Questions: Metastasis and the Invasion-Metastasis Cascade

Question 1

A biopsy of a primary breast tumor reveals cells with very low E-cadherin expression and high vimentin expression. What does this suggest about metastatic potential, and why?

• A. Low metastatic potential — without E-cadherin, cells cannot adhere to the basement membrane to form a stable tumor
• B. These markers indicate a non-invasive, highly differentiated tumor unlikely to spread
• C. These markers are evidence of epithelial-mesenchymal transition, suggesting cells have acquired mesenchymal properties enabling local invasion and intravasation
• D. These markers predict only lymph node spread, not hematogenous metastasis to distant organs

Answer: (C)

E-cadherin downregulation and vimentin upregulation are hallmarks of EMT — the transcriptional reprogramming that converts an epithelial cell into a mesenchymal, motile cell. EMT is driven by transcription factors like Snail, Slug, and Twist and is the first step enabling local invasion and vascular entry. Loss of E-cadherin allows cells to detach from neighbors; vimentin provides the cytoskeletal architecture for migration. These markers indicate a more aggressive, invasive phenotype.

Question 2

A patient's blood shows thousands of circulating tumor cells (CTCs) detected by liquid biopsy. Why is a high CTC count not equivalent to predicting widespread metastasis?

• A. CTCs in the blood are always dormant and never establish new colonies regardless of count
• B. Most CTCs are rapidly eliminated by immune surveillance, shear forces, and loss of matrix survival signals — only ~0.01% survive to colonize distant sites
• C. CTCs can only seed sites already seeded by prior micrometastases from the primary tumor
• D. Higher CTC counts indicate stronger immune surveillance, which paradoxically reduces metastatic risk

Answer: (B)

The invasion-metastasis cascade has multiple fatal bottlenecks. CTCs face anoikis (death from loss of matrix contacts), immune killing by NK cells, and mechanical shear stress in circulation. The vast majority are eliminated; those that survive often do so by clustering with platelets, which shield them from immune detection. CTCs are necessary but not sufficient for metastasis — colonization also requires a permissive microenvironment at the target site (the 'soil' in seed-and-soil theory). CTCs are biomarkers of disease activity, not a direct count of established metastases.

Question 3

A cancer cell that successfully enters the bloodstream (intravasates) has effectively achieved metastasis to distant sites.

• T. True
• F. False

Answer: False

Intravasation is one step in a multi-step cascade, not the endpoint. Most circulating tumor cells (~99.99%) are eliminated in circulation before they can colonize a new site. Even cells that survive to extravasate must then establish a colony in a permissive microenvironment. Many cells arrive at distant sites and remain dormant for years without forming clinically detectable metastases. Equating CTCs with metastasis conflates the process with its outcome and leads to overestimation of metastatic risk from liquid biopsy results.

Question 4

The 'seed and soil' hypothesis predicts that metastatic colonization depends not just on the cancer cell's properties but also on whether the target tissue provides a permissive microenvironment.

• T. True
• F. False

Answer: True

Paget's 1889 hypothesis — that metastatic 'seeds' (tumor cells) only grow in compatible 'soil' (target organ microenvironments) — is strongly supported by the non-random patterns of metastasis. Breast cancer preferentially seeds bone, lung, brain, and liver because breast cancer cells express receptors (e.g., CXCR4) for chemokines secreted by those target tissues (e.g., CXCL12 in bone marrow). A disseminated cell that lands in an incompatible environment either dies or remains dormant indefinitely.

Question 5

Why is metastatic potential not simply a fixed property predetermined by the primary tumor's genetic makeup, and what does this imply for treating recurrent disease?

Model answer: Metastatic potential emerges through ongoing clonal selection within the tumor. Not all cells in a primary tumor can metastasize — only those that have accumulated the right combination of mutations (EMT-enabling transcription factors, resistance to anoikis, ability to survive immune surveillance) are selected for. This selection continues after initial treatment: adjuvant therapy may eliminate the bulk tumor while leaving dormant micrometastases that harbor additional mutations. These cells can reactivate years later as a recurrence with a different molecular profile than the original tumor, often more resistant to the therapies that worked the first time.

The evolutionary framing is essential for clinical reasoning. Treating metastatic recurrence as if it were the same disease as the primary tumor often fails because it has been selected for further aggressiveness and drug resistance. Understanding dormancy — why some micrometastases lie silent for a decade before reactivating — is one of the central unsolved problems in cancer biology, with direct implications for the duration and targeting of adjuvant therapy.